Extended Data Fig. 3.

(A) PD-1 and CD39 staining on tetramer populations before (top) and after (bottom) DAA therapy. (B) Partitioning of scarred and reversed regions into those overlapping promoters, UTRs, exons, introns and intergenic areas as indicated. (C) Classification of SNPs falling within scarred, reversed or gained ChARs. SNPs that were subcategorized into those associated with chronic viral infection are summarized in Supplementary Table 3.